EU's gene-editing vote: how a patent deal was negotiated away in Europe's food future
The European Parliament's NGT regulation traded its own 2024 positions on patents and labeling for a negotiated compromise. Here's what the final deal actually contains — and what it doesn't.
The European Parliament votes on June 17 on a text that walks back two of the positions its own members had adopted eighteen months earlier. That evolution is acknowledged in official communiqués — but its significance has been largely underplayed in mainstream coverage. It sits at the heart of what the regulation on new genomic techniques — NGTs — actually reveals about how the European Union makes decisions when major industrial and agricultural interests converge.
The question is not, at its core, whether CRISPR-edited plants are dangerous to eat. It is more concrete, and more consequential: who will control Europe’s seeds in twenty years?
Key terms used in this article, explained below. Check glossary.
This image is used for illustrative purposes only.
At a Glance
On February 7, 2024 (confirmed by the full Parliament on April 24, 2024), MEPs voted to ban patents on NGT plants and require mandatory consumer labeling across the supply chain. The December 2025 trilateral agreement replaced those binding provisions with a voluntary code of conduct and transparency mechanisms — though it retained an exclusion list and a sustainability monitoring framework.
France voted in favor at the EU Council in April 2026 despite its own food safety agency, ANSES, calling for case-by-case evaluation and a broad democratic debate before any major decision.
Farmers growing traditional seed varieties could face infringement exposure if their crops naturally contain genetic sequences that industrial breeders have since patented through NGT modifications — a risk the final deal addresses partially, but not comprehensively.
What the regulation actually changes
Since a July 2018 ruling by the Court of Justice of the European Union (CJEU), plants produced through new genomic techniques have been legally classified as genetically modified organisms under existing EU law. The regulation going to a vote on June 17 would carve out a significant exemption from that framework.
The text divides NGT plants into two categories. Category 1 covers plants that have undergone a limited number of genetic modifications — deemed equivalent to varieties achievable through conventional breeding — and would be released from the authorization and labeling requirements that currently apply to GMOs. Consumers purchasing food products derived from Category 1 NGT plants would see no indication on the label. Only seed bags sold to farmers would carry an NGT label.
The final deal does include meaningful constraints on Category 1 eligibility. Herbicide tolerance and the production of known insecticidal substances are explicitly excluded from the category — plants with those intended traits are automatically classified as Category 2 and remain subject to full GMO authorization, traceability, and mandatory consumer labeling requirements. NGT plants of both categories are banned from organic farming. Member states may also opt out of cultivating Category 2 plants on their territory and can adopt coexistence measures to prevent unintended presence in other supply chains.
On patents, the agreement does not introduce a ban. Instead, it creates an expert group, a code of conduct for patent transparency and licensing, and requires applicants to declare all existing or pending patents when registering an NGT plant. The European Commission is also tasked with producing a study within one year of the first NGT market entries, assessing the impact on innovation, seed availability, and sector competitiveness — with the possibility of legislative follow-up.
Category 2 plants, with more complex modifications, remain subject to existing EU GMO legislation. Traditional first-generation transgenic GMOs — plants into which foreign DNA is inserted from another species — are entirely outside this regulation’s scope.
The patent question: what the trilogue traded away
When the Environment Committee of the European Parliament adopted its report on February 7, 2024, and the full Parliament confirmed that position on April 24, 2024 — by 307 votes in favor, 263 against, and 41 abstentions — MEPs had explicitly voted for a full ban on patents covering NGT plants, their derived seeds, genetic characteristics, and the processes used to produce them. They had also voted for mandatory labeling of all NGT-derived products across the full supply chain, including at the consumer level. The reasoning was clear: if a plant can be patented, it is not truly equivalent to a conventional variety.
Between May and December 2025, four rounds of trilogue negotiations brought together the European Commission, the EU Council, and Parliament representatives. The fourth session, on December 3, 2025, produced an agreement. The patent ban that MEPs had voted for was not retained. Mandatory consumer labeling for Category 1 products was also dropped. Both were replaced by the voluntary mechanisms described above.
This outcome was not concealed. Official communiqués from the Council acknowledged that “unlike Parliament’s original position, the agreement does not introduce a patent ban but strengthens transparency and monitoring mechanisms.” What the official framing elides, however, is the extent to which the Parliament’s negotiating team moved toward the Council’s position — and whether that movement adequately protects smaller operators.
Jessica Polfjärd, a Member of the European Parliament for the European People’s Party (EPP) representing Sweden, and the lead rapporteur on the file for the Parliament’s Environment Committee (ENVI), described the December 2025 agreement as “a breakthrough that boosts not only our farmers’ competitiveness, but also Europe’s position in research and innovation.” The Confédération Paysanne — France’s second-largest farm union — and the European Coordination Via Campesina (ECVC) characterized the same outcome as a “betrayal” of commitments made to farmers. Germany’s national farmers’ association, not generally known for anti-biotech activism, warned that introducing patents crossed what it called a “clear red line.”
The concrete risk is documented. If genetic sequences that already occur naturally in traditional or heritage seeds are later patented through NGT modifications, farmers whose crops contain those same sequences — through natural processes or cross-pollination — could find themselves exposed to intellectual property litigation. The code of conduct included in the agreement is voluntary; no enforcement mechanism applies if it is not followed.
Patent a genomic innovation, and you create structural dependency for anyone growing related varieties — voluntary codes of conduct have never altered that logic.
This concern is not hypothetical: North American case law has produced the precedents. The 2004 Supreme Court of Canada ruling in Monsanto Canada Inc. v. Schmeiser established that a farmer whose fields were contaminated by patented genetically modified crops could nonetheless be held liable for the presence of those genes in his harvest. The European legal framework differs in structure, but the underlying economic logic is identical.
What French institutional reports reveal
ANSES — France’s national food, environmental, and occupational health and safety agency, roughly equivalent to the U.S. Food and Drug Administration in its scientific advisory role — published a detailed assessment of NGT plants. It recommends a graduated, case-by-case evaluation rather than categorical deregulation. The agency identifies risks of off-target effects — mutations occurring in parts of the genome not targeted by the modification — which could affect a plant’s toxicity or nutritional composition. It also flags risks of gene flow toward wild plant species.
ANSES does not conclude that NGTs should be prohibited. It calls for structured governance and what it describes as “the broadest and most informed democratic debate possible,” arguing that NGTs raise choices that go beyond the scope of scientific expertise alone.
France’s Parliamentary Office for the Evaluation of Scientific and Technological Choices (OPECST, the French equivalent of the U.S. Office of Technology Assessment) published a scientific note in June 2025 raising a question that has received little public attention: the criteria used to classify a plant as Category 1 rest on defined thresholds of genetic modification. Researchers have challenged the scientific validity of the claim that such modifications could occur naturally. The note also flags the growing role of artificial intelligence in genomic engineering, which now enables modification combinations at a near-unlimited scale that the regulation’s current criteria did not anticipate.
France nonetheless voted in favor at the EU Council on April 21, 2026, alongside 17 other member states. Six voted against — Austria, Croatia, Hungary, Romania, Slovakia, and Slovenia — and three abstained (Germany, Belgium, and Bulgaria). This vote followed what the specialized agricultural press describes as a reversal: until late 2025, France had reportedly expressed reservations before swinging to a yes. The precise mechanics of that shift have not been made public in institutional documents.
The global picture: who controls the seeds?
The global seed market is dominated by a narrow oligopoly. After the merger wave of the 2010s, three groups hold the bulk of plant biotechnology patents: Bayer (which absorbed Monsanto in 2018), Syngenta (acquired by Chinese conglomerate ChemChina), and Corteva (spun out of the DowDuPont merger). These companies are the leading filers of plant genomic patents before the European Patent Office.
The European NGT framework would allow these actors to patent plants whose genomic characteristics are close to — or indistinguishable from — varieties produced through conventional breeding. The transparency declarations required under the new deal provide some visibility into the patent landscape. But without binding licensing obligations, knowing which patents exist does not guarantee access to the underlying plant material at affordable terms.
For small and mid-sized European seed companies — many of which rely on the Plant Variety Protection system, which protects the variety rather than the genetic sequence — the introduction of NGT-style patents represents a structural shift in competitive conditions. The Commission study due within one year of first market entries will be a key test of whether the voluntary safeguards are functioning as intended.
Analysis
The selective memory of the GMO debate
The EU effectively ended the cultivation of transgenic GMOs on its territory following an intense public and scientific debate from the late 1990s to the early 2000s. What that debate produced — strict regulation, the precautionary principle, mandatory labeling — is precisely what the NGT regulation rolls back for a subset of genetically modified plants. The argument put forward is that the techniques have changed: CRISPR is not Monsanto 810. That is true in a technical sense. What would be misleading is to assume that market structures have changed alongside them. The same firms that commercialized transgenic maize are today the dominant filers of NGT patents.
The mechanics of the trilogue and its limits
The EU’s co-decision system is premised on the idea that Parliament’s positions carry weight in interinstitutional negotiations. On NGTs, MEPs voted in early 2024 with clear positions on patents and labeling. Neither survived the trilogue intact. Several factors could account for this: pressure from the Polish Council presidency to reach an agreement before its term ended; the lead rapporteur’s choice to prioritize a comprehensive deal over specific guarantees; and the European Commission’s post-Draghi competitiveness agenda, which has positioned plant biotechnology as a vector of European industrial sovereignty. The Commission study and expert group built into the final deal represent a deferred accountability mechanism — meaningful only if its findings produce legislative action.
The concrete risk for farmers
The public debate focuses on food safety. The more immediate risk for independent operators is legal and economic. A small seed company that has marketed a variety for decades — containing a naturally occurring genetic sequence that a major breeder has since patented through an NGT modification — would have, under the current agreement, no binding guarantee of access to that material at reasonable terms. The code of conduct is the only safeguard, and it is voluntary.
The regulation’s structural contradiction
The text rests on a central claim: Category 1 NGT plants are equivalent to conventional varieties because their modifications could have occurred naturally. If that equivalence is genuine, the plants should not be patentable — patent law requires novelty that nature has not already produced. If they are patentable, they are not equivalent. The agreement’s response — transparency requirements and a future Commission study — defers rather than resolves this tension.
The Bottom Line
The June 17 vote will not settle whether NGTs are safe — Europe’s own food safety agencies have not concluded that they are inherently dangerous, and the exclusion of herbicide-tolerant and insecticidal traits from Category 1 reflects a genuine, if partial, application of the precautionary principle.
What the vote will settle is more structural: whether the voluntary safeguards on patents and licensing are sufficient to prevent a concentration of seed-market power that erodes the autonomy of Europe’s independent farmers and breeders. The Commission study due within a year of first NGT market entries will be the first real test of that answer.
If the answer is no — the question is whether the democratic and legislative mechanisms exist to course-correct before the dependencies become irreversible.
Sources: ANSES, risk and socioeconomic assessment of NGT plants (2024) · EU Council, press release on final adoption, April 21, 2026 · European Parliament, ENVI committee report adopted February 7, 2024; plenary position confirmed April 24, 2024 (2023/0226/COD) · OPECST, Scientific Note No. 47, June 2025 · European Commission, proposal COM/2023/411 · Court of Justice of the EU, judgment C-528/16, July 25, 2018
Glossary
NGT / NTG (science) — New Genomic Techniques: gene-editing methods such as CRISPR-Cas9 that alter a plant’s own DNA without inserting foreign genetic material. Distinct from first-generation GMOs.
GMO (science) — Genetically Modified Organism: a plant or animal whose DNA has been altered, often by inserting genes from another species. Strictly regulated in the EU since 2001.
CJEU (EU institution) — Court of Justice of the European Union: the EU’s highest court, based in Luxembourg. Its 2018 ruling classified NGT plants as GMOs under existing law.
ANSES (France) — France’s national food, environmental and occupational health agency. Broadly equivalent to the U.S. FDA in its scientific advisory role.
OPECST (France) — France’s parliamentary science advisory body, roughly equivalent to the U.S. Office of Technology Assessment.
EPP (EU politics) — European People’s Party: the EU Parliament’s largest center-right political group, which backed the NGT regulation. Jessica Polfjärd, the file’s lead rapporteur, is an EPP member.
ECVC (civil society) — European Coordination Via Campesina: a coalition of small-farmer organizations across Europe, affiliated with the global La Via Campesina movement. Co-organizer of the June 16 protest.
ENVI (EU institution) — Committee on the Environment, Climate and Food Safety: the European Parliament committee that drafted the NGT report and led trilogue negotiations.
Trilogue (EU process) — Informal three-way negotiations between the European Commission, the EU Council, and the European Parliament to finalize legislation. Sessions are not publicly broadcast.